A Pharmacist’s View of Emerging CML Treatment

EP: 1.NCCN Guidelines and Early Response Monitoring in Chronic Myeloid Leukemia

EP: 2.Shifting Therapeutic Urgency and TKI Strategy

EP: 3.Leveraging Trial Data to Guide Frontline TKI Use

EP: 4.Milestones That Matter: Using Molecular and Clinical Benchmarks to Guide CML Therapy

EP: 5.Reconsidering Later-Line Therapies in CML Management

EP: 6.The Pharmacist’s Role in Navigating Toxicity With TKIs

EP: 7.Expanding Pharmacist Roles in CML Care

EP: 8.Barriers to Accessing TKIs in CML

EP: 9.Overcoming Obstacles in CML Care

EP: 10.Gaps in CML Treatment in Underserved Populations

EP: 11.The Pharmacist’s Role in Treatment Evaluation

EP: 12.Optimizing Patient Treatment Adherence in CML

Now Viewing

EP: 13.A Pharmacist’s View of Emerging CML Treatment

A Pharmacist's View of Emerging CML Treatment

Several emerging advancements in chronic myeloid leukemia (CML) treatment offer promising improvements in patient outcomes. The most significant recent development is the addition of asciminib, the newest tyrosine kinase inhibitor (TKI) or STAMP inhibitor, to the frontline treatment armamentarium. This expansion provides clinicians with multiple therapeutic options ranging from first-generation imatinib to second-generation TKIs and now asciminib for initial treatment. This variety enables truly personalized treatment selection based on patient-specific factors, representing an exciting advancement in individualized CML care. Over time, these newer options have demonstrated equal or superior efficacy while offering improved tolerability profiles, which is particularly important for chronic disease states requiring long-term therapy.

Future therapeutic advances are anticipated across multiple areas of CML treatment. Ongoing investigations include dual TKI therapy for treatment-resistant disease, novel TKIs active against T315I-mutated CML, and optimal dosing strategies that maintain efficacy while ensuring long-term safety and tolerability. Clinical trials are also evaluating candidate selection criteria for TKI discontinuation, potentially offering patients the possibility of treatment-free remission. These developments represent significant hope for patients with treatment-resistant disease or T315I mutations, who currently face limited therapeutic options and represent a critical unmet medical need. Additionally, future advances may provide alternative options for patients experiencing adherence barriers.

Pharmacists play essential roles in educating both patients and providers about evolving treatment algorithms in the rapidly changing landscape of cancer therapy. Their ability to stay current with therapeutic updates, critically evaluate literature, and assess how changes impact treatment paradigms makes them invaluable team members. Pharmacists can compare available options, identify key differentiating factors for drug selection, and help providers understand monitoring parameters and toxicity management for newer agents. As the health care team gains experience with agents like asciminib, pharmacists facilitate learning about toxicity management and treatment navigation in data-sparse situations. Through patient education and promotion of shared decision-making, pharmacists ensure patients receive access to the newest therapeutic options while maintaining informed involvement in their care decisions.